In sum, these studies highlight that bispecific antibodies that simultaneously target CHI3L1 and CTLA-4 have prominent additive or synergistic anti-tumor effects in vivo and in vitro via its ability to induce CD8+ cytotoxic T cells and enhance tumor cell expression of PTEN. This evidence concerns the gene CD8A and neoplasm.